Search

everythinglearnresearchcommunity

for

Search:↓

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

Ritlecitinib was generally well tolerated in children with alopecia areata.

The treatment improved hair growth and thickness in patients with hair loss, even 10 months after therapy without additional products.

Hair and nail conditions can stabilize or improve over time, and new treatments show promise.

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

Combination therapy significantly reduces testosterone and moderately reduces hair growth in women with hirsutism.

Alopecia areata patients are more likely to have thyroid disorders than healthy individuals.

K10 may not prevent tumors as previously thought and might increase benign tumor risk.